Partner Investment Management’s Pacira BioSciences PCRX Stock Holding History

Partner Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-7,291	Closed	-$317K	–	89
2019 Q2	$317K	Buy	7,291 +4,118	+130%	+$175K	0.34%	61
2019 Q1	$121K	Sell	3,173 -2,978	-48%	-$116K	0.14%	79
2018 Q4	$265K	Sell	6,151 -24,882	-80%	-$1.16M	0.33%	64
2018 Q3	$1.52M	Sell	31,033 -7,211	-19%	-$312K	1.17%	32
2018 Q2	$1.23M	Buy	38,244 +14,446	+61%	+$499K	0.99%	36
2018 Q1	$741K	Buy	+23,798	New	+$847K	0.8%	46
2017 Q3	–	Sell	-36,119	Closed	-$1.72M	–	96
2017 Q2	$1.72M	Buy	36,119 +1,906	+6%	+$88.4K	2.31%	13
2017 Q1	$1.56M	Buy	34,213 +7,523	+28%	+$325K	1.9%	18
2016 Q4	$862K	Buy	+26,690	New	+$891K	1.14%	28

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Partner Investment Management's PCRX Position: Q3 2019 in Review

Partner Investment Management sold out of Pacira BioSciences (PCRX) in Q3 2019, closing a stake of 7,291 shares — an estimated $317K sold.

Partner Investment Management first reported a position in PCRX in Q4 2016 and held it in 9 quarters. The position peaked at $1.72M in Q2 2017. 211 funds tracked by Wall St. Rank hold PCRX as of Q3 2019.

Partner Investment Management reported no remaining Pacira BioSciences position as of Q3 2019 after selling out during the quarter.
Partner Investment Management sold 7,291 Pacira BioSciences shares in Q3 2019, an estimated $317K.
Partner Investment Management first reported a position in Pacira BioSciences in Q4 2016 and held it in 9 quarters.
Partner Investment Management's Pacira BioSciences position peaked at $1.72M in Q2 2017.
211 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2019.

Based on Partner Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.